The 8 Best Stem Cell Quotes of 2015

Stem Cells are Transforming the Future of Medicine

Stem cells are ushering in an age of regenerative medicine.

They are all over the news, because they will transform the next 50 years of medicine in ways that are now inconceivable.

In coming decades, stem cells will be reversing diseases ranging from Alzheimer’s to autism, re-growing organs and tissues, and potentially allowing the first humans to reach the age of 200.

Already in 2015, here are three “science fictions” that have become “science facts”… Continue reading The 8 Best Stem Cell Quotes of 2015

BioInformant Releases “Complete 2015-16 Induced Pluripotent Stem Cell Industry Report”

BioInformant announces release of its newest global strategic report, the “Complete 2015-16 Induced Pluripotent Stem Cell Industry Report.” The publication is an updated release of a prior 2013-14 version of the report published by BioInformant.

In the post below, we share with you an introduction to the report content. If you like our coverage of the iPSC industry, then please share this post with your peers who would also benefit from an increased understanding of iPSC market dynamics.

Overview Summary

Recent months have seen the first iPSC clinical trial in humans, creation of the world’s largest iPSC biobank, major funding awards, a historic challenge to the “Yamanaka Patent”, a Supreme Court ruling affecting industry patent rights, announcement of an iPSC cellular therapy clinic scheduled to open in 2019, and much more. Furthermore, iPSC patent dominance continues to cluster in specific geographic regions, while clinical trial and scientific publication trends give clear indicators of what may happen in the industry in 2015 and beyond.

Is it worth it to you to get informed about rapidly-evolving market conditions and identify key industry trends that will give you an advantage over your competition?

Report Applications

This global strategic report is produced for:

  • Management of Stem Cell Product Companies
  • Management of Stem Cell Therapy Companies
  • Stem Cell Industry Investors

It is designed to increase your efficiency and effectiveness in:

  1. Commercializing iPSC products, technologies, and therapies
  2. Making intelligent investment decisions
  3. Launching high-demand products
  4. Selling effectively to your client base
  5. Increasing revenue
  6. Taking market share from your competition

Continue reading BioInformant Releases “Complete 2015-16 Induced Pluripotent Stem Cell Industry Report”

Induced Pluripotent Stem Cells: Competitive Analysis of the U.S. Patent Landscape

Role of Patent Analysis for Competitive Intelligence

In 2006, groundbreaking experimentation led to the discovery of induced pluripotent stem cells (iPSCs), which are adult cells that are transformed into embryonic-like stem cells through the manipulation of gene expression or other related methods.  In 2007, follow-up experiments proved human adult cells could be transformed into iPSC cells.  Since the discovery of iPSCs, a large and thriving research product market has grown into existence, largely because the cells are completely non-controversial and can be generated directly from adult cells.

Today, the number of iPSC products sold worldwide is increasing with double-digit growth, and 22% of all stem cell researchers self-report having used iPSCs within a research project. It is clear that iPSCs represent a lucrative product market, but  commercializing the cell type involves careful and due diligence, because the cells are still a relatively new discovery.

Because the iPSC industry is a rapidly-evolving area, major research findings and technical discoveries are frequently announced . Therefore, to launch iPSC products and technologies, one of the key areas that company management and investors must consider is the patent landscape for the cell type.

Induced Pluripotent Stem Cell (iPSC) Patent Landscape

The United States federal government supports a searchable patent database, the “United State Patent and Trademark Office (USPTO) Full-Text and Image Database.”[2] It is a flexible and essential tool for analyzing the patent landscape  of any stem cell type.

When assessing a specific cell type, such as induced pluripotent stem cells, the USPTO patent database provides crucial information for several business intelligence (BI) metrics of importance, including: Continue reading Induced Pluripotent Stem Cells: Competitive Analysis of the U.S. Patent Landscape

If You’re Investing in the Cord Blood Market, You Need to Know These Metrics [Infographic]

Hematopoietic Stem Cells Transplant Rates, Utilization of Cord Blood, Awareness Rates, and More

The cord blood banking market has emerged gradually over the past 40 years, as 1974 was the first year in which it was proposed that stem and progenitor cells were present in human cord blood.[1]  In the forthcoming years it was established that cord blood stem cells had similar properties as bone marrow and could be used as an alternative.  Because it is a rich source of highly primitive hematopoietic stem cells, umbilical cord blood has enormous regenerative potential for stem cell based therapy, both for the treatment of hematological and non-hematological disorders.
Continue reading If You’re Investing in the Cord Blood Market, You Need to Know These Metrics [Infographic]

Marvelous Stem Cell Video by Harvard School of Medicine (3 Minutes)

Best Video of 2015:  “Birth and Engraftment of Blood Stem Cell”

This video published by the Harvard School of Medicine is incredible! We’ve passed it around and have awarded it the “Stem Cell Video of the Year” award.

It’s a zebrafish animation that shows the discoveries made by the Stem Cell Research Program at Boston Children’s Hospital.  Using the zebrafish as a model, it takes you from the birth of a blood stem cell, along its travel through the body, to its site of engraftment.

The importance of these findings is that they reveal the natural process of blood stem cell activity, the first time this activity has been documented within a living system, as discussed on the Harvard School of Medicine site here. Continue reading Marvelous Stem Cell Video by Harvard School of Medicine (3 Minutes)

Induced Pluripotent Stem Cell (iPSC) Market Accelerated by Landmark Events

The Landscape for Current iPSC Industry Conditions

Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSC). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods.

Research and experimentation using mouse cells at Kyoto University in Japan was the first instance in which there was successful generation of the iPSC. In 2007, a series of follow-up experiments were done at Kyoto University in which human adult cells were transformed into iPSC cells. Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.
Continue reading Induced Pluripotent Stem Cell (iPSC) Market Accelerated by Landmark Events

Business of Commercializing Induced Pluripotent Stem Cells [Infographic]

As a provider of induced pluripotent stem cell (iPSC) products and technologies, you need to make effective product development decisions, generate improved revenues, and take market share from your competition.

To do this, you need to be educated about prevailing market conditions. This involves knowing which stem cell types are showing the most promise and understanding methods through which these cells could be commercialized.

Stem cells are still a relatively new discovery, as the first stem cells were discovered in human cord blood in 1978, the first mouse embryonic stem cells were derived in 1981, and it was not until 2006 that induced pluripotent stem cells (iPSCs) were produced for the first time.
Continue reading Business of Commercializing Induced Pluripotent Stem Cells [Infographic]

Cord Blood Banking Industry: Key Benchmarks to Track (and Why You Should Care)

Recently released, the “Complete 2015-16 Global Cord Blood Banking Industry Report” reveals key benchmarks to track and why you should care. Benchmarks are critical to assess, because the global cord blood market has matured substantially over the past few years, creating both serious threats and novel opportunities.

Therefore, judging individual company performance relative to the broader cord blood marketplace has become substantially more complex.
Continue reading Cord Blood Banking Industry: Key Benchmarks to Track (and Why You Should Care)

Cord Blood Scholarly Research Round-Up [March 2015]

The cord blood banking market is rapidly evolving. Major research advances are announced every month. Innovation is the only constant.

Under these circumstances, it is difficult to tracking the ever-changing landscape of the cord blood banking market. Therefore, these scholarly research round-ups highlight “must know” research advances occurring in the sector, both those published by extremely well-regarded researchers (such as Joanne Kurtzberg’s article below), as well as those published by up-and-coming scientists.  Continue reading Cord Blood Scholarly Research Round-Up [March 2015]

Should Autologous Stem Cell Treatments Be Regulated As Drugs?

Autologous Stem Cells: Do They Belong to You?

An incredibly interesting aspect of the stem cell therapy market as it stands today is that autologous stem cell therapies are regulated by the U.S. Food and Drug Administration (FDA) as a drug.

Autologous means “from yourself,” and it is really as simple as that.  Stem cells, such as hematopoietic stem cells that have been used for decades in bone marrow transplants, can be extracted from an individual, and on the same day, can be re-injected into a specific site that needs repair to optimize health.

Regenexx Stem Cell Procedure

One of the most well-known of these approaches in the Regenexx procedure. You’ll have a very difficult time finding negative press about the procedure from patients, despite that many patients have paid several thousand dollars “out-of-pocket” to access the care, as it is typically not covered by health insurance carriers in the United States.

The reason is that the results are often outstanding. I am an example of a patient whose life was transformed by the procedure. I’m currently taking action to get access to my own “before” and “after” MRI of my knee damage that was addressed through stem cell regeneration.  I have my before MRI, but am in the process of acquiring my post-treatment MRI, as I just reach my one-year anniversary of the transplant.

In the meantime, here is a before and after MRI of another patient’s knee showing positive clinical results from the Regenexx procedure:

How Regulation of Autologous Stem Cell Procedures Affects the Global Stem Cell Market

As a stem cell research firm, the question that interests me most (and the question that will interest most of our readers who are executives at stem cell companies or stem cell industry investors) is how will the current regulation of autologous stem cells as a “drug” affect the broader stem cell marketplace?

If regulations in the United States that treat autologous stem cell as a drug do not change, then other countries, most notably Japan and Canada, but also United Kingdom, Australia, and others, will soon outpace the U.S. in this area of medicine.

Furthermore, for-profit companies in the U.S. will not have financial incentives to invest in the development of autologous stem cell treatments.

For the stem cell market at large, continued regulation of autologous stem cells as drugs within the United States will cause more money to flow overseas, followed by more jobs, more talent, and more futureresearch advances.  Without regulatory change, the epicenter of the stem cell market will not be the United States.  Japan is moving forward rapidly with stem cell based cellular therapy development, and in many respects, has already out-paced the U.S.

Are Stem Cells Different than Current Surgical Tissue Grafts?

When considering autologous stem cell regulation, an important question to ask is whether the use of autologous stem cells for therapeutic purposes  should be considered as substantially different than current procedures. For instance, in many surgical procedures, including traditional approaches to ACL repair, a graft is taken from another site of a patient’s body and placed into a different part of the body. One of the best-known examples of this is an approach for anterior cruciate ligament ( ACL) reconstruction that removes part of a patient’s hamstring tendon for use as a new ACL “substitute.” This procedure is known as Hamstring Tendon Graft Reconstruction (HTGR).

This comparison raises the question, are stem cells that have originated in you a “drug,” or you do and your doctor have a right to use them for therapeutic purposes, as surgeons have done for decades? 

“Special” and “Designer” Stem Cells

Naturally, there are different types of stem cells, and some come with greater complications and risks than others. For instance, there might be greater value in the regulation of stem cells that are sourced from another individual, a procedure known as an “allogenic” stem cell transplant. (“Allogenic” means coming from another.)

There are also embryonic stem cells (ESCs), which must be derived from embryos at fertility clinics. Note that the same embryos used to derive ESCs would be discarded or eventually die if they were not used to derive ESCs, because embryos cannot be indefinitely preserved. It is no more possible for an embryo to life indefinitely than it is for a human being to live forever.

There are also induced pluripotent stem cells (iPSC), which are adult cells that are reverse engineered to be pluripotent in nature, allowing them to have the potential to become a diverse range of adult cell types. Functionally, they are quite similar to embryonic stem cells in their therapeutic potential.

However, these “special” and “designer” stem cell types must not be compared to the basic hematopoietic stem cells that travel throughout an adult body, highly concentrated in specific regions such as the bone marrow. These autologous stem cells are intrinsic to every living being.

For that reason, I leave you today’s powerful quote, not as an answer, but as fuel for intellectual curiosity:

 Autologous Stem Cell Quote, Patient-Doctor InteractionNote: Click to enlarge image.

Enjoy, comment, in get in on this discussion of how autologous (“self”) stem cells should or should not be regulated!

Future Posts about the Stem Cell Industry

To receive future posts about the stem cell industry, sign-up here. We will never share your information with anyone, and you can opt-out at any time. No spam ever, just great stuff.

About Us

BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking.


Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data. To learn more about emerging opportunities and threats within the stem cell market, view our global strategic reports for the stem cell industry.

Case Law & Legal Updates for the Cord Blood Banking Market

Major Cord Blood Industry Change in 2015

Although we are only a few months in 2015, the cord blood banking market has already been experiencing rapid change.

The industry has seen structural advances occur, including a recent announcement of the Board of Directors for the Cord Blood Association, an  international nonprofit  that  promotes the  storage and use of cord blood and related tissues, such as cord tissue and placenta.

There have been major research advances as well. In one major example, a porcine animal study was conducted by the Mayo Clinic to evaluate the safety and feasibility of  cord blood-derived mononuclear cells (UBC-MNC) for use in promoting regeneration in pediatric congenital heart disease (CHD).

There have even been major clinical advances made already in 2015, with CryoSave leading and sponsoring a multicentre clinical trial following GCP-ICH standards, to determine if Cerebral Palsy can be addressed by infusing stem cells derived from umbilical cord blood and cord tissue into patients.

However, no understanding of the cord blood market is complete without a consideration of recent case law and significant legal decisions, which brings us to the focus on this market update.

Cord Blood Case Law & Legal Updates

Currently, there are three legal situations of which cord blood market participants should be aware: Continue reading Case Law & Legal Updates for the Cord Blood Banking Market

Geographical Breakdown of AABB Accredited Cord Blood Banks

Types of Accreditation for Cord Blood Banks

Within the United States, cord blood banks are subject to U.S. Food & Drug Administration (FDA) and state regulations. The FDA governs all aspects of cord blood preservation, including the collection, processing, storage, labeling, packaging, and distribution of cord blood stem cells. Within the United States, all cord blood banks must be registered with the FDA.

There are two different standards which can apply: cGTP (current Good Tissue Practices) and cGMP (current Good Manufacturing Practices)

  • cGTP standards apply to the collection, processing, and storage of human cells, tissues, and cellular/tissue based products (HCT/Ps), and are regulated by the Center for Biologics Evaluation and Research.[1] All U.S. cord blood banks must be compliant with cGTP standards.
  • cGMP standards apply to the manufacturing of a product that is considered a drug, and the determination for whether or not a cord blood bank must be compliant with cGMP standards is based upon the nature of the product that a facility manufactures. Because cGTP standards are based upon cGMP standards, there are many similarities between the two systems.

In addition, there are a number of other agencies in the U.S. that accredit cord blood banks. The primary optional accrediting agency for cord blood banks is the AABB (formerly the American Association of Blood Banks).   Continue reading Geographical Breakdown of AABB Accredited Cord Blood Banks

BIOINFORMANT’S MISSION: To be OMNIPRESENT in the Stem Cell and Cord Blood Marketplace

You Deserve Transparency

Some companies will not share their mission with you. They think it is top-secret information, private to them, something they have to hold under close guard.

This doesn’t make any sense.  We want you to have a clear understanding of our mission, because we want to serve you, partner with you, and most importantly, be fully transparent with you.

Therefore, here is BioInformant’s mission for 2015…

To be OMNIPRESENT in the stem cell and cord blood banking marketplace.

Educating You About the Stem Cell Space
Educating you about stem cell and cord blood markets, so you can make smarter decisions, faster.

Continue reading BIOINFORMANT’S MISSION: To be OMNIPRESENT in the Stem Cell and Cord Blood Marketplace

[Featured on] 4 Key Metrics You Need to Know to Invest in the Cord Blood Sector has posted an article titled, “4 Key Metrics You Need to Know to Invest in the Cord Blood Sector,” featuring BioInformant’s analytics for the cord blood banking market.

An excerpt is included below: 

“If you are an investor considering an opportunity within the cord blood market, the market can initially appear technical and confusing. However, if you focus on four key metrics, you can quickly and easily assess the technical attributes that matter, including market size, market potential, market competition, and market growth rates.”

Hematopoietic Stem Cell Transplant Rates

A trusted business partner of ours, has been selected by Inc. 5000 Magazine as one of America’s fastest growing private companies.

View full post